Lexaria Bioscience Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed on January 5, 2011, covering events occurring on January 4, 2011. The filing reports the unregistered sale of equity securities via warrant conversion.
Key Financial Metrics
- Proceeds Raised: CDN$14,586 (US$14,586).
- Shares Issued: 66,300 common shares.
- Warrants Converted: 132,600 warrants.
- Use of Proceeds: General working capital.
- Debt and Liquidity: The filing text does not provide a clear value for total debt, cash flow, or liquidity positions.
- Revenue and Profit: The filing text does not provide a clear value for revenue, profit, or margins.
Material Changes
The primary material change is the increase in outstanding common shares by 66,300 units resulting from the conversion of warrants. A significant portion of this transaction involved David DeMartini, the Company's Director, who converted 100,000 warrants into 50,000 shares.
Guidance, Risks, and Unusual Items
The securities were issued to two US persons pursuant to the exemption from registration under Rule 506 of Regulation D. Subscribers represented they were "accredited investors." The filing incorporates a press release regarding the closing of the private placement by reference. No specific forward-looking guidance or new risk factors were detailed in the text of this report.
Investor Verification Checklist
- Verify the total number of outstanding shares post-conversion.
- Confirm the conversion price per share implied by the proceeds and share count.
- Review the full text of the press release (Exhibit 99.1) for additional context on the private placement.
- Check subsequent filings for the actual deployment of the working capital proceeds.